Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation

AAPS Journal

Volumn 11, Issue 1, 2009, Pages 39-44

  Schlosburg, Joel E ^a   Kinsey, Steven G ^a   Lichtman, Aron H ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anandamide; CB1 cannabinoid receptor; CB2 cannabinoid receptor; Endogenous cannabinoid; Fatty acid amide hydrolase (FAAH); Inflammatory pain; Neuropathic pain

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; CANNABIS; CAPSAZEPINE; CARRAGEENAN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; FREUND ADJUVANT; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; UNCLASSIFIED DRUG; URB 602;

ALLODYNIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; COLITIS; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME INHIBITION; HYPERALGESIA; INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; PAW EDEMA; PHENOTYPE; RECEPTOR UPREGULATION; SHORT SURVEY; SKIN ALLERGY;

AMIDOHYDROLASES; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; GLYCERIDES; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; PAIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; POLYUNSATURATED ALKAMIDES; RATS; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; TETRAHYDROCANNABINOL; TRPV CATION CHANNELS;

EID: 65549121665     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9075-y     Document Type: Short Survey

References (62)

1. W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1946-1949 (1992).
2. R. Mechoulam, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:83-90 (1995).
3. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku. 2-Arachidonoyglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Comm. 215:89-97 (1995).
4. K. Ahn, M. K. McKinney, and B. F. Cravatt. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev. 108:1687-1707 (2008).
5. L. A. Matsuda, S. J. Lolait, M. J. Brownstein, A. C. Young, and T. I. Bonner. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:561-564 (1990).
6. C. M. Gerard, C. Mollereau, G. Vassart, and M. Parmentier. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J. 279(Pt 1):129-134 (1991).
7. M. Herkenham, A. B. Lynn, M. R. Johnson, L. S. Melvin, B. R. de Costa, and K. C. Rice. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11:563-583 (1991).
8. G. A. Cabral, E. S. Raborn, L. Griffin, J. Dennis, and F. Marciano-Cabral. CB2 receptors in the brain: Role in central immune function. Br. J. Pharmacol. 153:240-251 (2008).
9. M. D. Van Sickle, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 310:329-332 (2005).
10. D. Leung, A. Saghatelian, G. M. Simon, and B. F. Cravatt. Inactivation of N -acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry. 45:4720-4726 (2006).
11. G. M. Simon, and B. F. Cravatt. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/ beta-hydrolase 4 in this pathway. J. Biol. Chem. 281:26465-26472 (2006).
12. J. Liu, L. Wang, J. Harvey-White, D. Osei-Hyiaman, R. Razdan, Q. Gong, A. C. Chan, Z. Zhou, B. X. Huang, H. Y. Kim, and G. Kunos. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. USA. 103:13345-13350 (2006).
13. B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner, and N. B. Gilula. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:83-87 (1996).
14. B. F. Cravatt, K. Demarest, M. P. Patricelli, M. H. Bracey, D. K. Giang, B. R. Martin, and A. H. Lichtman. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. U S A. 98:9371-9376 (2001).
15. A. Saghatelian, M. K. McKinney, M. Bandell, A. Patapoutian, and B. F. Cravatt. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry. 45:9007-9015 (2006).
16. N. Ueda. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat. 68-69:521-534 (2002).
17. J. L. Blankman, G. M. Simon, and B. F. Cravatt. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 14:1347-1356 (2007).
18. P. Pacher, S. Batkai, and G. Kunos. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58:389-462 (2006).
19. A. G. Hohmann, and M. Herkenham. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. Neurosci. 90:923-931 (1999).
20. A. G. Hohmann, and M. Herkenham. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1171-1175 (1999).
21. V. Di Marzo, C. S. Breivogel, Q. Tao, D. T. Bridgen, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem. 75:2434-2444 (2000).
22. J. M. Walker, and A. G. Hohmann. Cannabinoid mechanisms of pain suppression. Handb. Exp. Pharmacol. 168: 509-554 (2005).
23. S. Kathuria, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9: 76-81 (2003).
24. A. H. Lichtman, C. C. Shelton, T. Advani, and B. F. Cravatt. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. 109:319-327 (2004).
25. A. H. Lichtman, D. Leung, C. C. Shelton, A. Saghatelian, C. Hardouin, D. L. Boger, and B. F. Cravatt. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311:441-448 (2004).
26. Z. Justinova, R. A. Mangieri, M. Bortolato, S. I. Chefer, A. G. Mukhin, J. R. Clapper, A. R. King, G. H. Redhi, S. Yasar, D. Piomelli, and S. R. Goldberg. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol. Psychiatry. 64(11):930-937 (2008).
27. J. Z. Long, W. Li, L. Booker, J. J. Burston, S. G. Kinsey, J.E. Schlosburg, F. J. Pavón, A. M. Serrano, D. E. Selley, L. H. Parsons, A. H. Lichtman, and B. F. Cravatt. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 5:37-44 (2009).
28. J. L. Croxford, and T. Yamamura. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. 166:3-18 (2005).
29. D. Richardson, R. G. Pearson, N. Kurian, M. L. Latif, M. J. Garle, D. A. Barrett, D. A. Kendall, B. E. Scammell, A. J. Reeve, and V. Chapman. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis research & therapy. 10:R43 (2008).
30. B. F. Cravatt, A. Saghatelian, E. G. Hawkins, A. B. Clement, M. H. Bracey, and A. H. Lichtman. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. USA. 101:10821-10826 (2004).
31. L. E. Wise, R. Cannavacciulo, B. F. Cravatt, B. F. Martin, and A. H. Lichtman. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology. 54:181-188 (2008).
32. B. Costa, S. Conti, G. Giagnoni, and M. Colleoni. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: Inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 137:413-420 (2002).
33. S. Holt, F. Comelli, B. Costa, and C. J. Fowler. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146:467-476 (2005).
34. M. D. Jhaveri, et al. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology. 55:85-93 (2008).
35. D. R. Sagar, D. A. Kendall, and V. Chapman. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 155(8):1297-1306 (2008).
36. C. Potenzieri, T. S. Brink, C. Pacharinsak, and D. A. Simone. Cannabinoid modulation of cutaneous A{delta} nociceptors during inflammation. J. Neurophysiol. 100(5):2794-2806 (2008).
37. A. Jayamanne, R. Greenwood, V. A. Mitchell, S. Aslan, D. Piomelli, and C. W. Vaughan. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147:281-288 (2006).
38. G. La Rana, R. Russo, P. Campolongo, M. Bortolato, R. A. Mangieri, V. Cuomo, A. Iacono, G. M. Raso, R. Meli, D. Piomelli, and A. Calignano. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J. Pharmacol. Exp. Ther. 317:1365-1371 (2006).
39. M. Karsak, et al. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science. 316:1494-1497 (2007).
40. A. A. Izzo, and A. A. Coutts. Cannabinoids and the digestive tract. Handb. Exp. Pharmacol. 168:573-598 (2005).
41. F. Massa, G. Marsicano, H. Hermann, A. Cannich, K. Monory, B. F. Cravatt, G. L. Ferri, A. Sibaev, M. Storr, and B. Lutz. The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest. 113:1202-1209 (2004).
42. M. A. Storr, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors. J. Mol. Med. 86:925-936 (2008).
43. G. D'Argenio, M. Valenti, G. Scaglione, V. Cosenza, I. Sorrentini, and V. Di Marzo. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J: Official publication of the Federation of American Societies for Experimental Biology. 20:568-570 (2006).
44. N. Attal, G. Cruccu, M. Haanpaa, P. Hansson, T. S. Jensen, T. Nurmikko, C. Sampaio, S. Sindrup, and P. Wiffen. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur. J. Neurol. 13:1153-1169 (2006).
45. L. R. Watkins, M. R. Hutchinson, A. Ledeboer, J. Wieseler-Frank, E. D. Milligan, and S. F. Maier. Norman Cousins Lecture. Glia as the "bad guys": Implications for improving clinical pain control and the clinical utility of opioids. Brain Behav. Immun. 21:131-146 (2007).
46. J. Zhang, C. Hoffert, H. K. Vu, T. Groblewski, S. Ahmad, and D. O'Donnell. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 17:2750-2754 (2003).
47. S. Petrosino, E. Palazzo, V. de Novellis, T. Bisogno, F. Rossi, S. Maione, and V. Di Marzo. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 52:415-422 (2007).
48. S. Mitrirattanakul, N. Ramakul, A. V. Guerrero, Y. Matsuka, T. Ono, H. Iwase, K. Mackie, K. F. Faull, and I. Spigelman. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain. 126:102-114 (2006).
49. I. Kaufmann, G. Schelling, C. Eisner, H. P. Richter, T. Krauseneck, M. Vogeser, D. Hauer, P. Campolongo, A. Chouker, A. Beyer, and M. Thiel. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology. 33:676-685 (2008).
50. R. Russo, J. Loverme, G. La Rana, T. R. Compton, J. Parrott, A. Duranti, A. Tontini, M. Mor, G. Tarzia, A. Calignano, and D. Piomelli. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J. Pharmacol. Exp. Ther. 322:236-242 (2007).
51. J. Desroches, J. Guindon, C. Lambert, and P. Beaulieu. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br. J. Pharmacol. 155(6):913-924 (2008).
52. L. Chang, L. Luo, J. A. Palmer, S. Sutton, S. J. Wilson, A. J. Barbier, J. G. Breitenbucher, S. R. Chaplan, and M. Webb. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148:102-113 (2006).
53. V. A. Mitchell, R. Greenwood, A. Jayamanne, and C. W. Vaughan. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin. Exp. Pharmacol. Physiol. 34:1186-1190 (2007).
54. M. Tognetto, S. Amadesi, S. Harrison, C. Creminon, M. Trevisani, M. Carreras, M. Matera, P. Geppetti, and A. Bianchi. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 21:1104-1109 (2001).
55. G. Horvath, G. Kekesi, E. Nagy, and G. Benedek. The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain. 134:277-284 (2008).
56. S. Maione, T. Bisogno, V. de Novellis, E. Palazzo, L. Cristino, M. Valenti, S. Petrosino, V. Guglielmotti, F. Rossi, and V. Di Marzo. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316:969-982 (2006).
57. B. Costa, F. Comelli, I. Bettoni, M. Colleoni, and G. Giagnoni. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. (2008), Epub ahead of print.
58. A. Singh Tahim, P. Santha, and I. Nagy. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience. 136:539-548 (2005).
59. J. Ahluwalia, L. Urban, S. Bevan, and I. Nagy. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci. 17:2611-2618 (2003).
60. Y. Sun, S. P. Alexander, D. A. Kendall, and A. J. Bennett. Cannabinoids and PPARalpha signalling. Biochem. Soc. Trans. 34:1095-1097 (2006).
61. J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, and D. Piomelli. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67:15-19 (2005).
62. V. L. Haller, D. L. Stevens, and S. P. Welch. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. Eur. J. Pharmacol. 600(1-3):50-58 (2008).